A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

Must have received: standard of care therapy

who have failed standard of care therapy, or are unable to tolerate standard of care therapy, or unable to obtain/unwilling to receive standard therapy

Cannot have received: PARG inhibitor

Any previous treatment with a PARG inhibitor

Cannot have received: chemotherapy

Exception: within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Cannot have received: immunotherapy

Exception: within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Cannot have received: radical radiotherapy

Exception: within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Cannot have received: targeted therapy

Exception: within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Cannot have received: palliative radiotherapy

Exception: within 2 weeks before the first dose

or received palliative radiotherapy within 2 weeks before the first dose

Cannot have received: other anti-tumor therapy

Exception: within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose

Cannot have received: anti-tumor therapy (clinical trial)

Exception: within 28 days before the first dosing, and the last dose of other anti-tumor trial drug is within 28 days prior to the first administration of study drug in this trial

Subjects who participated in any other clinical trial of anti-tumor therapy within 28 days before the first dosing, and the last dose of other anti-tumor trial drug is within 28 days prior to the first administration of study drug in this trial

Cannot have received: major surgery

Exception: within 4 weeks prior to the start of the study treatment, or scheduled to undergo a major surgery during the study period (procedures such as puncture or lymph node biopsy is allowed)

Subjects who underwent major surgery within 4 weeks prior to the start of the study treatment, or who are scheduled to undergo a major surgery during the study period (procedures such as puncture or lymph node biopsy is allowed)